Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

76 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia.
Mueller KT, Waldron E, Grupp SA, Levine JE, Laetsch TW, Pulsipher MA, Boyer MW, August KJ, Hamilton J, Awasthi R, Stein AM, Sickert D, Chakraborty A, Levine BL, June CH, Tomassian L, Shah SS, Leung M, Taran T, Wood PA, Maude SL. Mueller KT, et al. Among authors: august kj. Clin Cancer Res. 2018 Dec 15;24(24):6175-6184. doi: 10.1158/1078-0432.CCR-18-0758. Epub 2018 Sep 6. Clin Cancer Res. 2018. PMID: 30190371 Free PMC article.
A Phase I Study of Quizartinib Combined with Chemotherapy in Relapsed Childhood Leukemia: A Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study.
Cooper TM, Cassar J, Eckroth E, Malvar J, Sposto R, Gaynon P, Chang BH, Gore L, August K, Pollard JA, DuBois SG, Silverman LB, Oesterheld J, Gammon G, Magoon D, Annesley C, Brown PA. Cooper TM, et al. Clin Cancer Res. 2016 Aug 15;22(16):4014-22. doi: 10.1158/1078-0432.CCR-15-1998. Epub 2016 Feb 26. Clin Cancer Res. 2016. PMID: 26920889 Clinical Trial.
Inotuzumab ozogamicin in pediatric patients with relapsed/refractory acute lymphoblastic leukemia.
Bhojwani D, Sposto R, Shah NN, Rodriguez V, Yuan C, Stetler-Stevenson M, O'Brien MM, McNeer JL, Quereshi A, Cabannes A, Schlegel P, Rossig C, Dalla-Pozza L, August K, Alexander S, Bourquin JP, Zwaan M, Raetz EA, Loh ML, Rheingold SR. Bhojwani D, et al. Leukemia. 2019 Apr;33(4):884-892. doi: 10.1038/s41375-018-0265-z. Epub 2018 Sep 28. Leukemia. 2019. PMID: 30267011 Free PMC article.
Tisagenlecleucel Model-Based Cellular Kinetic Analysis of Chimeric Antigen Receptor-T Cells.
Stein AM, Grupp SA, Levine JE, Laetsch TW, Pulsipher MA, Boyer MW, August KJ, Levine BL, Tomassian L, Shah S, Leung M, Huang PH, Awasthi R, Mueller KT, Wood PA, June CH. Stein AM, et al. Among authors: august kj. CPT Pharmacometrics Syst Pharmacol. 2019 May;8(5):285-295. doi: 10.1002/psp4.12388. Epub 2019 Mar 7. CPT Pharmacometrics Syst Pharmacol. 2019. PMID: 30848084 Free PMC article.
Results from an international phase 2 study of the anti-CD22 immunotoxin moxetumomab pasudotox in relapsed or refractory childhood B-lineage acute lymphoblastic leukemia.
Shah NN, Bhojwani D, August K, Baruchel A, Bertrand Y, Boklan J, Dalla-Pozza L, Dennis R, Hijiya N, Locatelli F, Martin PL, Mechinaud F, Moppett J, Rheingold SR, Schmitt C, Trippett TM, Liang M, Balic K, Li X, Vainshtein I, Yao NS, Pastan I, Wayne AS. Shah NN, et al. Pediatr Blood Cancer. 2020 May;67(5):e28112. doi: 10.1002/pbc.28112. Epub 2020 Jan 15. Pediatr Blood Cancer. 2020. PMID: 31944549 Free PMC article. Clinical Trial.
76 results